Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Biotechnology
Merck & Co has announced that the Phase III KEYNOTE-B21 trial of its leading checkpoint blocker, Keytruda (pembrolizumab), has failed. 10 May 2024
Biotechnology
US biotech bluebird bio saw its shares close up almost 15% at $1.12 yesterday, after it reported first quarter 2024 results and business highlights, including recent commercial and operational progress. 10 May 2024
Biotechnology
California-based Attovia Therapeutics has announced the closing of a $105 million oversubscribed Series B financing. 9 May 2024
Pharmaceutical
On Wednesday, the American Heart Association (AHA)/American College of Cardiology (ACC) Joint Committee on Clinical Practice Guidelines issued a new clinical guideline for the evaluation and management of people with hypertrophic cardiomyopathy (HCM). 9 May 2024
Biotechnology
Part of a growing trend in the industry, Ligand Pharmaceuticals has inked a royalty financing agreement with immunology company Agenus. 9 May 2024
Biotechnology
New York-based biotech Regeneron Pharmaceuticals has announced highly encouraging results from a trial of its investigational gene therapy DB-OTO. 9 May 2024
Biotechnology
mRNA specialist Moderna has shared details of a year-old collaboration with artificial intelligence leader OpenAI. 8 May 2024
Biotechnology
Leading biotech incubator Flagship Pioneering has announced its latest investment, with the launch of a viral proteome start-up, Prologue Medicines. 8 May 2024
Biotechnology
Swedish Orphan Biovitrum has announced that the European Commission (EC) has approved an indication extension for Aspaveli (pegcetacoplan) to treat adults with paroxysmal nocturnal haemoglobinuria (PNH) who have hemolytic anemia. 8 May 2024
Biotechnology
US pharma giant Pfizer shared some sad clinical trial news Tuesday. 8 May 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze